The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes

Aliment Pharmacol Ther. 2011 Mar;33(5):559-65. doi: 10.1111/j.1365-2036.2010.04549.x. Epub 2010 Dec 29.

Abstract

Background: Acute hepatitis C has variable modes of presentation and frequently results in chronic infection. Its optimal management has yet to be defined.

Aim: To establish natural history and complications of treatment of acute hepatitis C.

Methods: Data from all patients presenting with acute hepatitis C to the National Institutes of Health between 1994 and 2007 were reviewed.

Results: Twenty-five patients were identified. Symptoms were reported by 80% and jaundice by 40%. Aminotransferase levels and hepatitis C virus (HCV) RNA levels fluctuated greatly; 18% of patients were intermittently negative for HCV RNA. Five patients recovered spontaneously whereas 20 developed chronicity or received interferon-based therapy during the acute phase. Among 15 patients treated during the acute phase with peginterferon with or without ribavirin for 24 weeks, all became HCV RNA negative within 4-8 weeks, and all except two (HIV-positive) achieved a sustained virological response. Side effects (particularly psychiatric) were common and limited treatment in 30%.

Conclusions: Among 25 patients with acute HCV infection, fluctuating illness was common and spontaneous recovery occurred in only 20%. Anti-viral treatment with a 24-week course of peginterferon and ribavirin was highly effective, but marked by frequent and severe side effects.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Antiviral Agents / adverse effects*
  • Disease Progression
  • Drug Therapy, Combination
  • Female
  • Hepatitis C / diagnosis*
  • Hepatitis C / drug therapy*
  • Hepatitis C / physiopathology
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Ribavirin / adverse effects*
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Ribavirin